23 September 2002 00:00 [Source: ICB Americas]CODEXIS Inc., a subsidiary of Maxygen Inc., received its first commercial payment and two separate milestone payments in its collaboration with Pfizer Inc. relating to improvements of the biosynthetic pathway in the production of a Pfizer drug. Codexis applied its MolecularBreeding directed molecular evolution technologies.
ELI LILLY and Company received an approvable letter from the Food and Drug Administration for Cym-balta (duloxetine), a dual reuptake inhibitor that works through two key neurotransmitters involved in depression-serotonin and norepinephrine.
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.